| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/21/2005 | WO2004108940A3 Viral genome vectors |
| 04/21/2005 | WO2004087746A3 Staphylococcus epidermidis antigens |
| 04/21/2005 | WO2004078918A3 Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides |
| 04/21/2005 | WO2004028455A3 Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 04/21/2005 | WO2004009802A3 gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS |
| 04/21/2005 | WO2003102164A3 Cancer-linked gene as target for chemotherapy |
| 04/21/2005 | WO2003063801A3 Treatment of tumor cells for use in immunotherapy of cancer |
| 04/21/2005 | WO2003049673A3 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 04/21/2005 | WO2002099053A3 Slc22as as modifiers of the p53 pathway and methods of use |
| 04/21/2005 | WO2002092842A3 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer |
| 04/21/2005 | WO2002092841A3 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 04/21/2005 | US20050086707 Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
| 04/21/2005 | US20050085627 Nucleotide sequences coding histone methyltransferase for use in identifying modulators for treatment and prevention of asthma disorders |
| 04/21/2005 | US20050085557 Oxidation of cholesterol in atherosclerosis plaque; cytotoxic |
| 04/21/2005 | US20050085434 Ballast administering to human skins; dna vaccine; high density core overcoated with amorphous reservoir containing dna |
| 04/21/2005 | US20050085433 Cellular vaccines comprising adjuvants |
| 04/21/2005 | US20050084966 Methods for inducing the differentiation of blood monocytes into functional dendritic cells |
| 04/21/2005 | US20050084947 Recombinant RSV virus expression systems and vaccines |
| 04/21/2005 | US20050084897 DNA encoding human vanilloid receptor VR3 |
| 04/21/2005 | US20050084860 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 04/21/2005 | US20050084845 Immunoglobulin specific to hepatitis c viral envelope protein for use as tool prevention and treatment of viral diseases |
| 04/21/2005 | US20050084524 Method for potentiating activity of a chemotherapeutic drug |
| 04/21/2005 | US20050084504 Methods for treating various disorders with a neurotoxic component of a botulinum toxin |
| 04/21/2005 | US20050084503 Continuous cell line for the production of vaccines |
| 04/21/2005 | US20050084502 Equine herpesvirus vaccine |
| 04/21/2005 | US20050084499 Comprises polypeptides for use in serodiagnosis and treatment of chlamydial sexually transmitted disease; vaccines |
| 04/21/2005 | US20050084498 EBV CTL epitopes |
| 04/21/2005 | US20050084497 Immunogens; replication-defective; antibodies; host cells; kits |
| 04/21/2005 | US20050084496 Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
| 04/21/2005 | US20050084495 Altering A B cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent |
| 04/21/2005 | US20050084491 Use as an immunogen to generate anti-integrin antibodies; a mimotope; vaccinating against angiogenic and metastatic diseases |
| 04/21/2005 | US20050084490 Boroproline compound combination therapy |
| 04/21/2005 | US20050084489 Synergistic administration of Vitaxin, a FAB fragment, or a competitive binding antibody for binding integrin alpha V beta 3 with the enzyme inhibitor; antiinflammatory, anticarcinogenic agents; autoimmune and metabolic bone disorders |
| 04/21/2005 | US20050084488 3-Hydroxy-4-aminomethylamido phosphorolane immunoconjugates used to elicit antibodies that catalyze the deamidation of asparagine to aspartic acid |
| 04/21/2005 | US20050084449 Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof |
| 04/21/2005 | CA2550583A1 Modified cea /b7 vector |
| 04/21/2005 | CA2548787A1 Antibody composition specifically binding to ganglioside gm2 |
| 04/21/2005 | CA2546730A1 A method for the treatment of malignant diseases by inhibiting nucleolin |
| 04/21/2005 | CA2542612A1 Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease |
| 04/21/2005 | CA2542608A1 Igf-i responsive gene and use thereof |
| 04/21/2005 | CA2542593A1 Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders |
| 04/21/2005 | CA2542295A1 Method |
| 04/21/2005 | CA2542130A1 Cell genomically modified to produce polypeptides with an altered glycosylation pattern |
| 04/21/2005 | CA2542099A1 Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| 04/21/2005 | CA2542044A1 Fully human antibodies against human 4-1bb (cd137) |
| 04/21/2005 | CA2542042A1 Antibody composition specifically binding to il-5 receptor |
| 04/21/2005 | CA2542037A1 Composition of antibody capable of specifically binding ccr4 |
| 04/21/2005 | CA2541833A1 Tyrosinase mutant and methods of use thereof |
| 04/21/2005 | CA2541804A1 Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer |
| 04/21/2005 | CA2541671A1 Bispecific antibody substituting for functional proteins |
| 04/21/2005 | CA2541464A1 Piscirickettsia salmonis antigens and use thereof |
| 04/21/2005 | CA2541360A1 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| 04/21/2005 | CA2539681A1 Nucleic acid molecules encoding novel human low-voltage activated calcium channel proteins, designated - alpha 1i-1 and alpha 1i-2, encoded proteins and methods of use thereof |
| 04/21/2005 | CA2539068A1 Hiv vaccines based on env of multiple clades of hiv |
| 04/21/2005 | CA2538418A1 Synthetic polysaccharide antigens for immunological intervention in disease |
| 04/21/2005 | CA2538093A1 Porifera-based therapeutic compositions for treating and preventing skin diseases |
| 04/21/2005 | CA2537473A1 Cytokine involved in epithelial-mesenchymal transition |
| 04/20/2005 | EP1523992A1 Vaccine formulation against Gumboro disease |
| 04/20/2005 | EP1523991A1 Anti-cancer vaccine |
| 04/20/2005 | EP1523990A1 Cellular vesicles denoted as 'exosomes', their preparation and use in the stimulation of an immune response |
| 04/20/2005 | EP1523989A1 Anti cancer vaccine derived from autologous plasma or leucocytes |
| 04/20/2005 | EP1523582A2 Rapid, efiicient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 04/20/2005 | EP1523577A2 Method for diagnosis of intestinal-type gastric tumors |
| 04/20/2005 | EP1523559A1 Cell wall mutants for delivery of biologically active compounds |
| 04/20/2005 | EP1523557A2 Antigens encoded by alternative reading frame from pathogenic viruses |
| 04/20/2005 | EP1523499A2 Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| 04/20/2005 | EP1523497A2 HSP70 FROM i ARTHROBACTER /i |
| 04/20/2005 | EP1523496A2 Recombinant production of mixtures of antibodies |
| 04/20/2005 | EP1523492A2 Igg fc/hiv-gp120/c3d fusion protein |
| 04/20/2005 | EP1523372A2 Ghrelin-carrier conjugates |
| 04/20/2005 | EP1523334A2 Hapten-carrier conjugates and uses thereof |
| 04/20/2005 | EP1523332A1 Medicament for the treatment of diseases due to infection by neisseria meningitidis |
| 04/20/2005 | EP1523331A2 Therapeutic tb vaccine |
| 04/20/2005 | EP1523330A2 Vaccine against salmonid rickettsial septicaemia based on arthrobacter cells |
| 04/20/2005 | EP1523329A2 Adjuvant viral particle |
| 04/20/2005 | EP1206547B1 Moraxella catarrhalis antigen basb117 |
| 04/20/2005 | EP1206546B1 Moraxella catarrhalis antigen basb120 |
| 04/20/2005 | EP1141326B1 Human akt-3 |
| 04/20/2005 | EP1068226B1 Lipopeptides inducing t lymphocytic cytotoxicity bearing at least one auxiliary t epitope, and uses for vaccination |
| 04/20/2005 | EP1009753B1 Hypoxia-regulated genes |
| 04/20/2005 | EP0917471B1 Treatment and diagnosis of infections of gram positive cocci |
| 04/20/2005 | EP0871704B1 Transcriptional co-repressor that interacts with nuclear hormone receptors and uses therefor |
| 04/20/2005 | EP0759995B1 Fusion glycoprotein from hcmv and hsv |
| 04/20/2005 | EP0700430B1 Methods for selectively stimulating proliferation of t cells |
| 04/20/2005 | CN1608062A Salt forms of e-2-methoxy-n-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 04/20/2005 | CN1607960A Glycoprotein compositions |
| 04/20/2005 | CN1607959A Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| 04/20/2005 | CN1607942A Pharmaceutical compositions in particulate form |
| 04/20/2005 | CN1607941A Pharmaceutical compositions in particulate form |
| 04/20/2005 | CN1607247A Dendritic cell tumor vaccine and its preparation and use |
| 04/20/2005 | CN1607207A S protein of SARS virus, its vaccine and method for screening medicament using it |
| 04/20/2005 | CN1607006A Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| 04/20/2005 | CN1607005A Soluble lymphotoxin- beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| 04/20/2005 | CN1607004A Recombinant foot-and-mouth disease virus VP1 confluent protein vaccine |
| 04/20/2005 | CN1197966C Modulators of TNF receptor associated factor (TRAF), their preparation and use |
| 04/20/2005 | CN1197961C BHV-1 gene-deleted virus vaccine |
| 04/20/2005 | CN1197898C Nucleic compound and production method thereof, and its use in the preparation of immune formulation |
| 04/20/2005 | CN1197877C AsLc-IFN fusion protein and its preparation |
| 04/20/2005 | CN1197620C Use of immidazoquinolinamines as adjuvants in DNA vaccination |
| 04/20/2005 | CN1197619C Biological therapy adjuvant originated from animal Chinese medicine |